Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3719
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Trang, T. T. T., Thư, G. T. A., Dương, B. V., Hợp, H. T. B., Hảo, H. T. L., & Hạnh, N. T. H. (2025). 44. Occurrence and risk factors of chemotherapy-induced neutropenia among breast cancer patients receiving chemotherapy at Hanoi Oncology Hospital. Journal of Medical Research, 192(7), 416-429. https://doi.org/10.52852/tcncyh.v192i7.3719

44. Occurrence and risk factors of chemotherapy-induced neutropenia among breast cancer patients receiving chemotherapy at Hanoi Oncology Hospital

Tran Thi Thu Trang, Giap Thi Anh Thu, Bach Van Duong, Han Thi Bich Hop, Hoang Thi Le Hao, Nguyen Thi Hong Hanh

Main Article Content

Abstract

This study described the characteristics and investigated several factors related to neutropenia in 118 breast cancer patients receiving chemotherapy at Hanoi Oncology Hospital (437 chemotherapy cycles). Thirty-four patients (28.8%) experienced at least one episode of neutropenia, 15 patients had severe neutropenia (12.7%), and 5 patients had complications related to neutropenia (6.0%). Univariate analysis showed that high-risk regimens significantly increased the risk of any degree of neutropenia; treatment during cycle 1 increased the rate of severe neutropenia, and renal dysfunction along with previous complications of neutropenia increased the rate of neutropenia-related complications. Patients with a history of neutropenia at any level or severe neutropenia had an increased likelihood of developing recurrent neutropenia (both any-level and severe) (p < 0,05). Multivariate analysis identified several factors that significantly increased the risk of neutropenia of any grade and severe neutropenia, including high-risk regimens, treatment in cycle 1, and a history of neutropenia in previous cycles. It is necessary to further develop a predictive model for factors increasing the risk of neutropenia to optimize prophylactic strategies for each patient based on real-world data.

Article Details

Keywords

Chemotherapy-induced neutropenia, febrile neutropenia, granulocyte colony-stimulating factor, G-CSF, breast cancer

References

1. Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treatment Reviews. 2022/09/01/ 2022; 109: 102427. doi:https://doi.org/10.1016/j.ctrv.2022.102427.
2. Dessalegn M, Fantahun M, Yesufe AA, Hussein M, Tsegaye A. Chemotherapy Induced Neutropenia, Febrile-Neutropenia and Determinants Among Solid Cancer Patients Attending Oncology Unit of a Tertiary Care Teaching Hospital in Ethiopia. Cancer management and research. 2023; 15: 185-195. doi:10.2147/cmar.S386181.
3. Mucenski JW, Shogan JE. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor. J Manag Care Pharm. Mar-Apr 2003; 9(2 Suppl): 10-4. doi:10.18553/jmcp.2003.9.s2.10.
4. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. Jan 2011; 47(1): 8-32. doi:10.1016/j.ejca.2010.10.013.
5. Bộ Y tế. Sốt và giảm bạch cầu trung tính trên bệnh nhân sử dụng hóa trị. Hướng dẫn thực hành lâm sàng cho dược sỹ trong một số bệnh không lây nhiễm. Nhà xuất bản Y học; 2019: 329-335.
6. Bộ Y tế. Sốt do giảm bạch cầu ở bệnh nhân ung thư. Hướng dẫn chẩn đoán và điều trị một số bệnh Ung bướu. Nhà xuất bản Y học; 2020: 26-34.
7. National Comprehensive Cancer Network. Hematopoietic Growth Factors (Version 1.2025). NCCN; 2025.
8. Hoàng Thị Phương, Trần Thị Thu Trang, Nguyễn Thị Thảo, Nguyễn Thị Thanh Hiền, Nguyễn Văn Thắng. Thực trạng dự phòng biến cố giảm bạch cầu trung tính do hóa trị liệu trên bệnh nhân ung thư tại Bệnh Viện Phụ Sản Trung Ương. Tạp chí Y học Việt Nam. 2025; 547(3): 157-162.
9. Trần Thị Thu Trang, Dương Khánh Linh, Đỗ Huyền Nga, Phùng Quang Toàn, Nguyễn Thị Hồng Hạnh, Nguyễn Thị Liên Hương. Thực trạng dự phòng biến cố giảm bạch cầu trung tính do hóa trị liệu bằng thuốc tăng sinh bạch cầu (G-CSF) trên bệnh nhân ung thư vú và u lympho tại Bệnh Viện K. Tạp chí Y học Việt Nam. 2020; 488(2): 225-229.
10. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services; 2017: 88.
11. American Cancer Society. How Common Is Breast Cancer? American Cancer Society. Accessed April 3, 2025. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html.
12. Moore DC. Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia. Pt. Dec 2016; 41(12): 765-768.
13. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2015/10/01 2015; 33(28): 3199-3212. doi:10.1200/JCO.2015.62.3488.
14. Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm. Mar-Apr 2003; 9(2 Suppl): 15-21. doi:10.18553/jmcp.2003.9.s2.15.
15. Clemons M, Fergusson D, Simos D, et al. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Annals of Oncology. 2020/07/01/ 2020; 31(7): 951-957. doi:https://doi.org/10.1016/j.annonc.2020.04.005.